Skip to main contentAll experts

Mark Segal

SR ASO DEAN & PROF

MD-MEDICINE

Orcid identifier0000-0002-5502-2042 (opens in a new tab)⁠
  • SR ASO DEAN & PROF
    MD-MEDICINE

GRANTS

  • GRANT
    Molecular mechanisms regulating peripheral arterial disease pathobiology in chronic kidney disease
    National Institute of Health Nhlbi7 Jul 2026 - 30 Apr 2031
    Active
  • GRANT
    EASi-KIDNEY, Studies of Heart & Kidney Protection with BI 690517 in combination with empagliflozin: A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease
    University of Oxford3 Jun 2026 - 2 Jun 2031
    Active
  • GRANT
    Medical Scientist Training Program at the University of Florida
    National Institute of Health Nigms3 Jun 2026 - 30 Jun 2031
    Active
  • GRANT
    INSiGHTS - Innovative Next Steps in Gaining Health Improvements Through Translational Science
    National Institute of Health Ncats18 Aug 2025 - 30 Jun 2032
    Active
  • GRANT
    A prospective, multicenter, single arm, open-label, early feasibility study to evaluate initial safety and device design concept of “HyperQureTM RDN System”, laparoscopic renal denervation therapy, in patients with resistant antihypertensive on three (3) or more antihypertensive medications
    Deepqure8 May 2025 - 11 May 2030
    Active
  • GRANT
    Studies of Heart & Kidney Protection with BI 690517 in combination with empagliflozin: A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease
    Boehringer Ingelheim Pharm Inc3 Sep 2024 - 2 Sep 2029
    Active
  • GRANT
    A LONG-TERM FOLLOW-UP STUDY OF PARTICIPANTS EXPOSED TO RENAL AUTOLOGOUS CELL THERAPY (REACT) FROM STUDIES RMCL-002, REGEN-003, REGEN-004
    Prokidney20 Dec 2023 - 12 Sep 2024
    Closed
  • GRANT
    Together: Transforming and Translating Discovery to Improve Health
    National Institute of Health Ncats1 Jul 2023 - 30 Jun 2025
    Expired
  • GRANT
    A PHASE 3 RANDOMIZED CONTROLLED STUDY OF RENAL AUTOLOGOUS CELL THERAPY (REACT) IN SUBJECTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE (REGEN-006)
    Prokidney23 Mar 2023 - 22 Mar 2028
    Active
  • GRANT
    Outcomes and perspectives on treatment for critical limb ischemia in patients with end-stage renal disease
    National Institute of Health Nhlbi29 Jul 2022 - 31 Jul 2027
    Active
  • GRANT
    Together: Transforming and Translating Discovery to Improve Health
    National Institute of Health Ncats1 Jul 2022 - 30 Jun 2024
    Expired
  • GRANT
    A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants Who Have Thrombotic Microangiopathy Associated With a Trigger
    Alexion Pharmaceuticals31 Mar 2022 - 18 Jan 2024
    Closed
  • GRANT
    Chronic aryl hydrocarbon receptor activation and skeletal myopathy in chronic kidney disease
    15 Jul 2021 - 7 May 2024
    Expired
  • GRANT
    Development and Validation of Computational Algorithms to Assess Kidney Health in Electronic Health Records
    National Institute of Health Niddk8 Apr 2020 - 31 Oct 2024
    Expired
  • GRANT
    Molecular Mechanisms regulating peripheral arterial disease pathobiology in chronic kidney disease
    National Institute of Health Nhlbi29 Nov 2019 - 31 Jul 2026
    Expired
  • GRANT
    A multicentre international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess cardio-renal outcomes in patients with chronic KIDNEY disease
    Boehringer Ingelheim Pharm Inc10 Oct 2019 - 9 Oct 2024
    Closed
  • GRANT
    Sex Differences in Chronic and Acute Vascular Responses to Aerobic Exercise in Older Adults
    National Institute of Health Nia20 Aug 2019 - 31 May 2024
    Expired
  • GRANT
    A multicentre international randomized parallel group double-blind placebo controlled clinical trial of EMPAgliflozin once daily to assess cardio-renal outcomes in patients with chronic KIDNEY disease
    Boehringer Ingelheim International Gmbh21 Dec 2018 - 18 Mar 2022
    Closed
  • GRANT
    A PHASE 2 PROSPECTIVE, RANDOMIZED, DOUBLE-ARM, DEFERRED TREATMENT, OPEN-LABEL, REPEAT DOSE, SAFETY AND EFFICACY STUDY OF AUTOLOGOUS NEO KIDNEY AUGMENT™ (NKA) IN SUBJECTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE
    Regenmed (Cayman) Ltd29 Oct 2018 - 28 May 2024
    Closed
  • GRANT
    Hydroxychloroquine for the Management of CVD in CKD (opens in a new tab)⁠
    United States Department of Veterans Affairs1 Oct 2018 - 30 Sep 2026
    People funded by this grant:
    • SHUKLA AM,
    • SEGAL MS
    MORELEARN MORE (opens in a new tab)
  • GRANT
    A PHASE II, OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF AN AUTOLOGOUS NEO-KIDNEY AUGMENT (NKA) IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE (REGEN-003)
    Regenmed (Cayman) Ltd13 Sep 2018 - 16 Nov 2020
    Closed
  • GRANT
    PICS: A New Horizon for Surgical Critical Care
    1 Jun 2018 - 31 May 2020
    Expired
  • GRANT
    The SPRINT-Alzheimer’s, Seniors, and Kidney Study (SPRINT ASK)
    National Institute of Health Nia3 Oct 2017 - 31 Dec 2018
    Expired
  • GRANT
    Frequent, Low-Dose Erythropoietin: A Mechanistic Approach to Mitigate Adverse Cardiovascular Effects of Erythropoietin Therapy in Patients with Chronic Kidney Disease (opens in a new tab)⁠
    United States Department of Veterans Affairs1 Oct 2017 - 31 Oct 2019
    People funded by this grant:
    • SEGAL MS
    MORELEARN MORE (opens in a new tab)
  • GRANT
    PICS: A New Horizon for Surgical Critical Care
    15 May 2017 - 31 May 2018
    Expired